Cardiometabolic Disease: Molecular Basis and Therapeutic Approaches

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 853

Special Issue Editors


E-Mail Website
Guest Editor Assistant
1. Department of Cardiology, Preventive Cardiology & Heart Failure Outpatient Clinic, Sismanogleio-Amalia Fleming General Hospital, 14 25is Martiou Street, 15127 Melissia, Greece
2. School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias, 11527 Athens, Greece
3. NT-CardioMetabolics, Clinic for Metabolism and Athletic Performance, 47 Tirteou Street, 17564 Palaio Faliro, Greece
Interests: cardiometabolic medicine; cardiovascular endocrinology and metabolism; preventive cardiology and rehabilitation; heart failure; cardiogeriatrics; clinical epidemiology

E-Mail Website
Guest Editor
Department of Cardiology, Preventive Cardiology & Heart Failure Outpatient Clinic, Sismanogleio-Amalia Fleming General Hospital, 14 25is Martiou Street, 15127 Melissia, Greece
Interests: cardiometabolic medicine; cardiovascular endocrinology and metabolism; preventive cardiology and rehabilitation; heart failure; cardiogeriatrics; clinical epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Cardiometabolic diseases, including type 2 diabetes mellitus, obesity, hypertension, dyslipidemia, and metabolic syndrome, have reached pandemic proportions. These interconnected conditions elevate the risk of atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, non-alcoholic fatty liver disease, obstructive sleep apnea, and polycystic ovary syndrome, creating a vicious cycle of worsening metabolic dysregulation and poor outcomes. Recent advances, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, have reshaped therapeutic strategies, demonstrating efficacy across cardiometabolic diseases and crossing traditional specialty boundaries.

This Special Issue of Biomolecules invites high-quality original research articles and comprehensive reviews on molecular mechanisms, biomarkers, and innovative therapies for cardiometabolic diseases. By bridging basic science and clinical practice, it aims to foster interdisciplinary collaboration and highlight translational research to improve patient outcomes.

In this Special Issue, submissions may cover (but are not limited to) the following themes:

  • Pathophysiological mechanisms driving cardiometabolic diseases;
  • Identification and validation of novel therapeutic targets and biomarkers;
  • The use of novel anti-diabetic therapies and hormonal therapies in the management of cardiometabolic diseases;
  • Insights into lifestyle interventions and their impact on cardiometabolic outcomes.

We look forward to receiving your contributions and collaborating on this important initiative to advance the field of cardiometabolic research.

Dr. Nikolaos Theodorakis
Guest Editor Assistant

Dr. Maria Nikolaou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiometabolic medicine
  • preventive cardiology
  • cardiovascular endocrinology and metabolism
  • obesity
  • diabetes mellitus
  • cardiovascular disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

24 pages, 1648 KiB  
Perspective
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
by Nikolaos Theodorakis and Maria Nikolaou
Biomolecules 2025, 15(2), 213; https://doi.org/10.3390/biom15020213 - 2 Feb 2025
Viewed by 262
Abstract
Cardiometabolic diseases represent an escalating global health crisis, slowing or even reversing earlier declines in cardiovascular disease (CVD) mortality. Traditionally, conditions such as obesity, type 2 diabetes mellitus (T2DM), atherosclerotic CVD, heart failure (HF), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver [...] Read more.
Cardiometabolic diseases represent an escalating global health crisis, slowing or even reversing earlier declines in cardiovascular disease (CVD) mortality. Traditionally, conditions such as obesity, type 2 diabetes mellitus (T2DM), atherosclerotic CVD, heart failure (HF), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease (MASLD) were managed in isolation. However, emerging evidence reveals that these disorders share overlapping pathophysiological mechanisms and treatment strategies. In 2023, the American Heart Association proposed the Cardiovascular-Kidney-Metabolic (CKM) syndrome, recognizing the interconnected roles of the heart, kidneys, and metabolic system. Yet, this model omits the liver—a critical organ impacted by metabolic dysfunction. MASLD, which can progress to metabolic dysfunction-associated steatohepatitis (MASH), is closely tied to insulin resistance and obesity, contributing directly to cardiovascular and renal impairment. Notably, MASLD is bidirectionally associated with the development and progression of CKM syndrome. As a result, we introduce an expanded framework—the Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome—to more comprehensively capture the broader inter-organ dynamics. We provide guidance for an integrated diagnostic approach aimed at halting progression to advanced stages and preventing further organ damage. In addition, we highlight advances in medical management that target shared pathophysiological pathways, offering benefits across multiple organ systems. Viewing these conditions as an integrated whole, rather than as discrete entities, and incorporating the liver into this framework fosters a more holistic management strategy and offers a promising path to addressing the cardiometabolic pandemic. Full article
(This article belongs to the Special Issue Cardiometabolic Disease: Molecular Basis and Therapeutic Approaches)
Show Figures

Figure 1

Back to TopTop